Zobrazeno 1 - 10
of 35
pro vyhledávání: ''
Publikováno v:
Alimentary Pharmacology & Therapeutics. 37:1165-1171
Summary Background Success in H. pylori eradication with conventional therapies has decreased to unacceptable levels (≤80%). New schemes of combined treatment are currently needed. Aim To test a miscellaneous therapy for H. pylori eradication. Meth
Publikováno v:
Alimentary Pharmacology & Therapeutics. 36:37-47
Summary Background To date, the safety and tolerability of proton pump inhibitors (PPIs) have been demonstrated in studies of up to 10 years. Aim To report on the tolerability, safety and efficacy of up to 15 years' continuous treatment with pantopra
Autor:
G. N. J. Tytgat
Publikováno v:
Alimentary Pharmacology & Therapeutics. 9:39-42
Virtually all duodenal ulcers (DUs) and the vast majority of gastric ulcers (GUs) are the consequence of Helicobacter pylori-associated inflammation. In DUs, the inflammation is maximal in the antrum and is associated with gastric metaplasia in the b
Publikováno v:
Alimentary Pharmacology & Therapeutics. 9:705-709
SUMMARY Background: Aim of this work was to improve standardization of the 13C-urea breath test (13C-UBT) by evaluating the effect of drug administration, feeding and colonic ureolysis on the UBT results. Methods: Three different studies were perform
Autor:
C. P. Dooley
Publikováno v:
Alimentary Pharmacology & Therapeutics. 5:129-143
Helicobacter pylori attracted widespread interest from gastroenterologists because of its potential aetiologic role in disorders of the upper gastrointestinal tract. Based on extensive microbiological studies, Campylobacter pylori was renamed Helicob
Autor:
Francesco Nardi, P. Crispino, M. Rivera, Omero Alessandro Paoluzi, D. Ferro, Paolo Paoluzi, A. Consolazio, M. C. Borgia, Federico Iacopini
Publikováno v:
Alimentary Pharmacology & Therapeutics. 20:289-294
Summary Background : Conflicting data have been reported concerning the relationship between Helicobacter pylori infection and coronary heart disease. Aim : To evaluate clotting system activation and plasma levels of tumour necrosis factor-α, a proc
Autor:
Hidekazu Suzuki, T. Hibi, K. Nomoto, H. Goshima, N. Kamata, Tatsuhiro Masaoka, Masaki Kitajima, Sachiko Nomura, Y. Kodama, Hiromasa Ishii
Publikováno v:
Alimentary Pharmacology & Therapeutics. 20:185-192
Recently, chicken egg yolk was recognized as an inexpensive antibody source, and the therapeutic usefulness of egg yolk immunoglobulin Y (IgY) in oral passive immunization has been investigated. Although multiple antibiotic treatments eradicate most
Autor:
Ken Haruma, Atsunori Sasaki, S. Tanaka, Masaharu Yoshihara, Jiro Hata, Masanori Ito, Tomoari Kamada, Hiroaki Kusunoki
Publikováno v:
Alimentary Pharmacology & Therapeutics. 18:245-252
Summary Aim : To investigate whether curing Helicobacter pylori infection improves symptoms over the long-term in Japanese patients with nonulcer dyspepsia and fundic atrophic gastritis. Methods : Ninety H. pylori-positive dyspeptic patients with fun
Autor:
Takayuki Matsumoto, Kazuhide Higuchi, Tetsuya Tanigawa, Toshio Watanabe, Takashi Takashima, Masaki Hamaguchi, Kazunari Tominaga, Eiji Sasaki, Yasuhiro Fujiwara, Masatsugu Shiba, T Arakawa, Nobuhide Oshitani
Publikováno v:
Alimentary Pharmacology & Therapeutics. 18:1-7
Background and Aims: The effects of rebamipide on chronic gastritis associated with Helicobacter pylori have not been well-defined. We compared these effects of rebamipide with those of cimetidine in Mongolian gerbils infected with H. pylori. Methods
Autor:
Robert M. Genta
Publikováno v:
Alimentary Pharmacology & Therapeutics. 18:8-13
Rebamipide stimulates the generation of endogenous prostaglandins in the gastric mucosa and is reported to accelerate ulcer healing. This review discusses whether rebamipide can prevent Helicobacter pylori infection, reduce inflammation, accelerate h